RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
RT @SStattner: Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic opti…
Our next paper is out and freely (open access) available. We extensively looked at oligometastatic PDAC and therapeutic options in 2019. https://t.co/rON0c2IKVe Thanks for the cooperation Heidelberg pancreatic center @FPrimavesi @SpringerNature @ESSOnews @